2024
PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY
Leapman M, Rabil M, Ghaffar U, Long J, Westvold S, Sprenkle P, Kim I, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Kluetz P, Kunst N, Wang S, Ma X, Gross C, Karnes R. PD45-10 PROSTATE-SPECIFIC MEMBRANE ANTIGEN IMAGING FINDINGS AND SUBSEQUENT CLINICAL MANAGEMENT AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: A RETROSPECTIVE COHORT STUDY. Journal Of Urology 2024, 211: e971. DOI: 10.1097/01.ju.0001008792.09108.b4.10.Peer-Reviewed Original ResearchPD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING
Kunst N, Long J, Westvold S, Sprenkle P, Rabil M, Ghaffar U, Kim I, Saperstein L, Wang S, Ma X, Gross C, Leapman M. PD08-10 EFFECTIVENESS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN POSITRON EMISSION TOMOGRAPHY AMONG PATIENTS WITH BIOCHEMICAL RECURRENT PROSTATE CANCER: RESULTS OF DECISION ANALYTIC MODELING. Journal Of Urology 2024, 211: e177. DOI: 10.1097/01.ju.0001008576.33217.96.10.Peer-Reviewed Original ResearchProstate cancerPatients
2021
Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer
Yang SC, Kunst N, Gross CP, Wang JD, Su WC, Wang SY. Cost-Effectiveness of Nivolumab Plus Ipilimumab With and Without Chemotherapy for Advanced Non-Small Cell Lung Cancer. Frontiers In Oncology 2021, 11: 760686. PMID: 34956882, PMCID: PMC8695441, DOI: 10.3389/fonc.2021.760686.Peer-Reviewed Original ResearchNon-small cell lung cancerIncremental cost-effectiveness ratioMetastatic non-small cell lung cancerCell lung cancerHealth care sector perspectivePD-L1Lung cancerAdvanced non-small cell lung cancerPD-L1 expression levelsCycles of chemotherapyProgression-free survivalFirst-line treatmentCost-effectiveness ratioExpression levelsCheckMate 227Overall survivalSubgroup analysisLifetime horizonOutcome dataChemotherapyPatientsIpilimumabNivolumabQALYSector perspectiveTrends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years
Richman IB, Long JB, Kunst N, Kyanko K, Xu X, Busch S, Gross CP. Trends in Breast Cancer Screening Costs Among Privately Insured Women Aged 40 to 64 Years. JAMA Internal Medicine 2021, 181: 1665-1668. PMID: 34459853, PMCID: PMC8406208, DOI: 10.1001/jamainternmed.2021.4832.Peer-Reviewed Original ResearchEarly Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers
Jongeneel G, Greuter M, Kunst N, van Erning F, Koopman M, Medema J, Vermeulen L, Ijzermans J, Vink G, Punt C, Coupé V. Early Cost-effectiveness Analysis of Risk-Based Selection Strategies for Adjuvant Treatment in Stage II Colon Cancer: The Potential Value of Prognostic Molecular Markers. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1726-1734. PMID: 34162659, PMCID: PMC7611620, DOI: 10.1158/1055-9965.epi-21-0078.Peer-Reviewed Original ResearchConceptsConsensus molecular subtypesStage II colon cancerGuideline strategyEarly cost-effectiveness analysisColon cancer deathsPrognostic molecular markersMarkov cohort modelDutch societal perspectiveCancer treatment selectionCost-effectiveness analysisAdjuvant chemotherapyAdjuvant treatmentCancer deathCost-effectiveness assessmentMolecular subtypesTreatment selectionCurrent evidenceColon cancerSocietal perspectiveDecision uncertaintyMolecular markersCohort modelPatientsMarkersVOI analysis